Trial Profile
A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Chronic Kidney Disease Stages 3b to 5 and With Hyperphosphataemia Not on Dialysis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Colestilan (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Registrational
- Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation
- 26 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 16 Oct 2013 New trial record